Share the Video:

How do psychedelics work?

Robin Carhart-Harris is a psychologist and neuroscientist and Head of the Centre for Psychedelic Research, Division of Brain Sciences, Faculty of Medicine at Imperial College London. He coordinated the first clinical study of psilocybin in the UK and the first clinical study of a classic psychedelic drug in the UK for over 40 years. After being awarded an MA in Psychoanalysis at Brunel University, London, Carhart-Harris completed his Ph.D. in psychopharmacology at the University of Bristol. In 2009, under the mentorship of Professor David Nutt, he relocated to Imperial College London to continue his fMRI research with the classic psychedelic psilocybin. In conjunction with David Nutt, he built up a program of psychedelic research that includes fMR and MEG imaging with psilocybin, fMR imaging with MDMA, and plans for an MRC-sponsored clinical trial to assess the efficacy of psilocybin as a treatment for major depression.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Pragmatic Trial of Psilocybin Therapy in Palliative Care: A Multicenter Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life

Overview of a multicenter trial compares psilocybin therapy to active control for demoralization in end-of-life adults. Trial focuses on treating depression, anxiety, and improving quality of life, spiritual well-being, and

Jessi Humphreys

PS2023 Depression Health Conditions Psilocybin Psychedelic Assisted Therapy Psychedelic Science Research

Psychedelics and Sexual Functioning: a Mixed-Method Study in Healthy and Depressed Subjects

Psychedelics, historically linked to "free love", show potential for positive impact on sexual feelings. Recent research suggests psilocybin may enhance sexual functioning and satisfaction in healthy and depressed individuals.

Tommaso Barba

PS2023 Depression Psilocybin Psychedelic Assisted Therapy Psychedelic Science Research and Science Substance Use Disorder

Psychedelics: Spirituality, Mindfulness, and Mortality – Personal reflections and visions for the future

Roland Griffiths, Ph.D., from Johns Hopkins University, leads research on psilocybin's effects, including therapeutic studies for psychological distress, depression, addiction, and brain imaging for neural mechanisms.

Roland Griffiths

PS2023 Depression Psilocybin Psychedelic Assisted Therapy Psychedelic Science Research and Science Therapy Ethics

Psilocybin-assisted Therapy for Major Depressive Disorder: Clinical Results and Cases From a Placebo-controlled, Fixed-order Trial

Dr. Sloshower presents results from a psilocybin-assisted therapy study for major depression, showing larger antidepressant effects than placebo, with lasting mood improvements. Dr. Kilpatrick discusses longitudinal case studies.

Jordan Sloshower, Stephanie Kilpatrick

PS2023 Depression Integration Psilocybin Psychedelic Assisted Therapy Psychedelic Science Research

Psychedelics as relational medicines: Investigating the role of psychosocial factors for outcomes of clinical and naturalistic psychedelic use

Psychedelics are studied for psychiatric disorders; research emphasizes 'set and setting.' Study explores psychosocial factors in psychedelic use, linking communal experiences to improved mental health outcomes.

Hannes Kettner

PS2023 Depression Health Conditions Psilocybin Psychedelic Assisted Therapy Psychedelic Science Research

New Directions for Psychedelic Therapies: Exploring Psilocybin in Alzheimer's Disease and Chronic Lyme Disease

Psilocybin's therapeutic potential for various medical conditions is being explored, including pilot studies on Alzheimer's Disease and chronic Lyme Disease. Preliminary results and participant reports inform ongoing psilocybin-assisted treatments research.

Albert Garcia-Romeu

PS2023 Ayahuasca Psilocybin Psychedelic Assisted Therapy Psychedelic Science Research Research and Science

Mind-bending, mind–“mending”? The effect of psychedelics on flexible cognition, and underlying neural mechanisms

Psychedelic drugs may enhance creative thinking and empathy, supported by anecdotal reports and some scientific evidence. Studies show time- and construct-dependent effects on flexible cognition, with brain imaging linking changes

Natasha Mason

PS2023 Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Public Benefit Research Research and Science

What Will People Think? Revealing Public Knowledge, Belief, and Perceptions of Psychedelics

Imran Khan presents findings of the Psychedelic Insight Poll, a national survey by the Berkeley Center for the Science of Psychedelics to understand public perceptions of psychedelic substances. The poll

Imran Khan

PS2023 Health Conditions Psilocybin Psychedelic Assisted Therapy Psychedelic Science Research Therapy Ethics

Family Matters in Psychedelic Therapy: Lessons Learned from a Psilocybin Trial for Anorexia Nervosa

Family involvement in psychedelic therapy can optimize outcomes and prevent problematic patterns. Ethical, neurobiological, and psychological aspects, along with clinical trial data, support the benefits of engaging family members.

Jennifer Danby

How do psychedelics work?

Become a MAPS Member with a monthly donation

Related Videos